Myeloid Hematologic Malignancy
1 clinical trials · Condition
◉ Watch Myeloid Hematologic Malignancy
| Record | Firm | Date |
|---|---|---|
| Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies (NCT03082677) | Memorial Sloan Kettering Cancer Center | 2017-03-10 |
Track Myeloid Hematologic Malignancy automatically
Every clearance here is in the API, with alerts when new ones post.